NEW YORK (GenomeWeb News) – The American College of Obstetricians and Gynecologists has issued an opinion that non-invasive prenatal testing using cell-free fetal DNA can be offered to patients at increased risk of aneuploidy — a decision that is favorable to firms such as Sequenom, Ariosa Diagnostics, and Verinata Health.